Use of Carbapenems, Polymyxins, and Tigecycline in United States Children’s Hospitals, 2010–2014
Kathleen Chiotos, Rachael K. Ross, Jennifer Han, Matthew R. Miller, Jeffrey S. Gerber
Abstract
Open-access reader
Kathleen Chiotos, Rachael K. Ross, Jennifer Han, Matthew R. Miller, Jeffrey S. Gerber
Abstract
Open-access reader
We characterized use of the carbapenems, polymyxins, and tigecycline in United States children's hospitals between 2010 and 2014. We found substantial variability in use across hospitals and overall decreased use over time. Most polymyxin and tigecycline use occurred in cystic fibrosis patients, and appendectomy was a common indication for carbapenem therapy.
OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
We characterized use of the carbapenems, polymyxins, and tigecycline in United States children's hospitals between 2010 and 2014. We found substantial variability in use across hospitals and overall decreased use over time. Most polymyxin and tigecycline use occurred in cystic fibrosis patients, and appendectomy was a common indication for carbapenem therapy.
Key concepts: Tigecycline, Medicine, Polymyxin, Carbapenem, Intensive care medicine, Colistin, Polymyxin B, Antibiotics